Exchange: NASDAQ·Updated 05:26 PM EST

CAMP News

News
all
press releases
CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +15.00% and -5.52%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +15.00% and -5.52%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +8.33% and +31.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Talent is often one of the earliest indicators of a biotechnology company's long-term ambitions. That theme was reinforced this week as CAMP4 Therapeutics (NASDAQ:CAMP) announced an inducement equity award to a newly hired employee under Nasdaq Listing Rule 5635(c)(4), a standard mechanism that allows listed companies to use equity grants as a recruiting incentive for new hires. While modest in size, an option to purchase 8,000 shares, the announcement signals continued investment in building the team behind CAMP4's clinical-stage pipeline.
24-7 Market News
AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.
Zacks
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 468,369...
MarketBeat

Advertisement|Remove ads.